Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGHT vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGHT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–1 Matrix Metrics)
SGHT Overall Winner
6-Pillar Tally: SGHT 3 – 2 BMRA (1 Tie)
Matrix Metrics: SGHT 7 – 1 BMRA
As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.62 (N/M Forward P/E, -20.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).
- Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -125.2% operating margin) and revenue trajectory (+25.2% vs. -8.3% YoY).
- Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SGHT vs BMRA
SGHT
Head-to-Head Winner
Sight Sciences, Inc. Common Stock
$10.62
-1.94% 1D
Market Cap
$610.8M
TTM Revenue
$88M
Forward P/E
N/M
Beta / 30D Vol
1.06β · 46% Vol
Unified Composite Score
35.1
SELL
Tech 50.0
Fund 32.0
Flow 57.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
BMRA
Biomerica Inc
$1.33
-2.32% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SGHT 3 – 2 BMRA)
1. Valuation Multiples
BMRA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.5x
1.1x
2. Growth & Scale
SGHT
Revenue Growth (YoY)
+25.2%
-8.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$88M
$4.3M
Market Cap
$610.8M
$6.0M
3. Profitability & Quality
SGHT
Gross Margin
87.7%
0.9%
Operating Margin
-20.2%
-125.2%
Net Profit Margin
-32.1%
-115.5%
Return on Equity (ROE)
-50.1%
-113.8%
4. Balance Sheet & Cash Flow
BMRA
Cash Generation (TTM)
-$17M
-$3.2M
Cash Flow Margin
-19.1%
-73.5%
Net Cash / Leverage
$35M Net Cash
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGHT
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
78.7% (8th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGHT (7) vs BMRA (1)| Institutional Metric | SGHT | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $610.8M | $6.0M | SGHT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +25.2% | -8.3% | SGHT | |
| Operating Margin (TTM) | -20.2% | -125.2% | SGHT | |
| Net Profit Margin | -32.1% | -115.5% | SGHT | |
| Return on Equity (ROE) | -50.1% | -113.8% | SGHT | |
| 52-Week Range Position | 88% ($3–$12) | 4% ($1–$3) | SGHT | |
| Beta / 30D Volatility | 1.06β · 46% Vol | 0.67β · 62% Vol | SGHT | |
| Unified Institutional Score | 35.1 / 100 (SELL) | 44.5 / 100 (HOLD) | BMRA | |
| Trailing 12M Revenue (USD) | $88M | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 87.7% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.5x EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($35M Net Cash) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SGHT +56.45 pp
3M Horizon
SGHT +46.17 pp
6M Horizon
SGHT +159.48 pp
1Y Horizon
SGHT +97.5 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SGHT Revenue | BMRA Revenue | SGHT Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -46.4% | BMRA |
| FY2020 | $30M | $10M | -116.5% | -41.0% | BMRA |
| FY2021 | $50M | $10M | -105.2% | -104.2% | BMRA |
| FY2022 | $70M | $20M | -117.7% | -24.0% | BMRA |
| FY2023 | $80M | $10M | -70.7% | -135.3% | SGHT |
| FY2024 | $80M | $10M | -63.3% | -117.6% | SGHT |
| FY2025 | $80M | $10M | -48.0% | -96.7% | SGHT |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SGHT
BREAKOUT
Current IV
78.7%
IV Percentile
8th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SGHT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SGHT vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.62 (N/M Forward P/E, -20.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -125.2% operating margin) and revenue trajectory (+25.2% vs. -8.3% YoY). Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SGHT cumulative revenue shifted +166.7% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
BMRA screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (-19.1% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.06β · 46% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs SGHT · Reverse Pair
SGHT vs CTKB
· Sector Peer
SGHT vs TMCI
· Sector Peer
SGHT vs RXST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking